They are good without being exceptional, which is what some were hoping for.
Reality is that if the primary endpoint was met, a partnership would be on the cards.
As it wasn't- it's a wait and see proposition and hopefully the full phase 2 results show the treatment beating placebo, or else it's a dead program.
That's the reason why people have jumped ship, the risk profile is higher now compared to looking at NASH through the lens of a phase 1 trial on very small populations.
Goodluck!
IMC Price at posting:
22.5¢ Sentiment: Buy Disclosure: Held
